Altris AI introduces Flags to instantly identify OCT scans with specific retina pathologies or biomarkers

Chicago, IL – August 26, 2025 – Altris AI introduces an advanced flagging system to search through the large volumes of OCT scans, including historical data.

Now, with Altris AI’s new functionality, eye care professionals can instantly identify OCT scans with specific retina pathologies or biomarkers from the list of over 70 conditions. For example, clinicians can locate OCT scans of all patients with a Soft Drusen or Dry AMD, forming cohorts for clinical or research purposes.

For those who work with Geographic Atrophy biomarkers, it is also possible to exclude the presence of GA biomarkers in 1, 3,6 mm ETDRS zones to spot early development of this pathology.

The flagging system is precise and enables fast, targeted searches across historical records and large datasets – including OCT scans from different devices. This advancement supports a more efficient workflow and enhances access to critical data for both diagnostics and research.

“Flags are a clinical shortcut. Instead of manually searching through thousands of scans, you can now filter precisely for what you need—whether that’s subretinal fluid, GA progression, or early glaucoma indicators. It’s about making the data work for you.” Maria Znamenska, MD, PhD, Chief Medical Officer at Altris AI.

With flags for smart filtering, eye care specialists can:

• Track risk-related biomarkers and set reminders for patient follow-ups
• Quickly identify eligible candidates for clinical studies by searching through large volumes of data
• Confidently introduce new treatments by finding the right patient profiles
• Filter rare or complex cases to study unique combinations of pathologies and biomarkers and their progression

“Flags make it possible to build patient cohorts in minutes,” Maria Znamenska, Chief Medical Officer at Altris AI, comments on this new feature. “Whether it’s for the research or for introducing the new therapy, you now have a reliable tool to search for the right patients efficiently.

For example, the FDA has recently approved the first treatment for Macular Telangiectasia Type 2, so eye care specialists can now search through their whole patient database and find those who have this particular pathology in minutes to offer them a new treatment.”

The release of flags reinforces Altris AI’s position as a leading AI decision support platform for OCT analysis for both clinical care and research purposes. By enabling customizable filtering across over 70 pathologies and biomarkers, flags support better disease tracking, faster research, and more personalized treatment planning.

About Altris AI
Altris AI is a vendor-neutral, web-based AI Decision Support for OCT Analysis platform. It supports early diagnosis, treatment planning, and research across more than 70 biomarkers and retinal pathologies. Altris AI is used by leading clinics and research centers worldwide.